Alnylam to Webcast Presentations at Upcoming February Investor Conferences
BIO CEO& Investor Conference on Monday, February 11, 2019at 1:30 pm ETat the Marriott Marquis in New York City
SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019at 10:30 am ETat the Lotte New York Palace Hotelin New York City
A live audio webcast of each presentation will be available on the Investors section of the Company’s website, www.alnylam.com. A replay will be available on the Alnylam website within 48 hours after each event.
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference
(RNAi) into a new class of innovative medicines with the potential to
improve the lives of people afflicted with rare genetic,
cardio-metabolic, hepatic infectious, and central nervous system
(CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi
therapeutics represent a powerful, clinically validated approach for the
treatment of a wide range of severe and debilitating diseases. Founded
in 2002, Alnylam is delivering on a bold vision to turn scientific
possibility into reality, with a robust discovery platform. ONPATTRO®
(patisiran) lipid complex injection, available in the U.S. for the
treatment of the polyneuropathy of hereditary transthyretin-mediated
(hATTR) amyloidosis in adults, is Alnylam’s first U.S.
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)